BTCC
/
BTCC Square
/
Global Cryptocurrency
/
MBX Biosciences Stock Surges 138% on Positive Phase 2 Trial Results
MBX Biosciences Stock Surges 138% on Positive Phase 2 Trial Results
12
2
BTCCSquare news:
MBX Biosciences shares more than doubled in premarket trading after announcing successful Phase 2 results for its hypoparathyroidism treatment candidate canvuparatide. The clinical-stage biopharmaceutical company reported 63% of treated patients met the primary endpoint, with 79% achieving responder status at six months in the extension study.
CEO Kent Hawryluk emphasized these results demonstrate meaningful improvement over existing HP treatments, positioning the therapy for Phase 3 development. The peptide prodrug aims to address chronic hypoparathyroidism, a disorder characterized by insufficient parathyroid hormone production.
By:
